Coronary artery disease
Transforming complex PCI procedures into confident care
As the prevalence of coronary artery disease (CAD) grows globally, interventional cardiologists are feeling the strain. With an ever-increasing case load and a squeeze on resources, delivering efficient, cost-effective and high-quality care presents significant challenges. At Philips, we also recognize that the cath lab is a complex landscape, made up of different information and systems. Philips offers a fully integrated ecosystem designed to meet today’s challenges can provide you more information faster, which enhances cath lab performance and which ultimately can support confident decisions and exceptional patient care. Moreover, our smart management of X-ray dosage is there to enhance patient care.
Improving lab performance while focusing on the patient
Philips coronary suite has advanced clinical and workflow applications, therapeutic and diagnostic devices, and leading services, all working together to efficiently support every step of coronary procedures. From diagnosis to restoring vessel patency, the Coronary suite ecosystem is designed to enhance performance and efficiency today, while serving as your launching pad to the future: Imagine if you could aggregate system performance data to improve departmental performance. Imagine if you could aggregate all patient cardio data to improve procedural decision making.
Philips is your partner of choice when it comes to coronary interventions
When you invest in Philips Coronary suite, you are investing in a path to future technological advancements and capabilities. As we move from a mainly transactional to a value-based pathway in healthcare, integration, usability and artificial intelligence will drive the industry forward. It’s exciting to think of what’s possible when care providers can access the tools and technologies they need to create a fully integrated and transformed interventional cardiology service.
Resources
Explore what Philips image-guided therapy has to offer for PCI
-
![Percutaneous coronary intervention]()
Percutaneous coronary intervention
Solutions for coronary artery disease for PCI procedures offered by Philips image-guided therapy.
Click here to learn more
Key products of Coronary suite
Azurion
Experience the new world of interventional cardiac and vascular performance with the Azurion 7 Series with 12'' flat detector.
IntraSight
The IntraSight applications platform is where imaging, physiology, co-registration1 and software all come together to clearly identify coronary and peripheral artery disease, and allow for more optimized treatment plans.
iFR modality
iFR is the gold standard among resting indices backed by patient outcomes that reduces costs, procedural time and patient discomfort2-4 while providing advance guidance with co-registration.
Integrated cardiology solutions
Explore an integrated cardiology ecosystem of data and devices working together to help you provide efficient and effective cardiac care in the most appropriate setting.
Personalized solution for ambulatory surgery centers
CMS approved low-risk percutaneous coronary intervention (PCI) for ASCs giving physicians opportunities to safely treat patient populations diagnosed with coronary artery disease. Philips SymphonySuite is here to help you transition to an ASC or build a new ASC from the ground up.
Want to talk to a sales representative or stay informed?
Complete the form and we will get back to you.
References
1. Co-registration tools available within IntraSight 7 configuration via SyncVision. 3. Götberg M, Christiansen EH, Gudmundsdottir IJ, et al. iFR-SWEDEHEART Investigators. Instantaneous Wave-free Ratio versus Fractional Flow Reserve to Guide PCI. N Engl J Med. 2017;376:1813-18234. 4. Davies JE, Sen S, Dehbi HM, et al. Use of the Instantaneous Wave-free Ratio or Fractional Flow Reserve in PCI. N Engl J Med. 2017;376: 1824-1834.
2. Patel M. “Cost-effectiveness of instantaneous wave-Free Ratio (iFR) compared with Fractional Flow Reserve (FFR) to guide coronary revascularization decisionmaking.” Late-breaking Clinical Trial presentation at ACC on March 10, 2018.